Educational Activities

Show Filters
Hide Filters
1-6 of 13 Activities
Title
Availability
Format
Credits
Course Opens
Buttons

2022 EGFR+ Lung Cancer Rapid Recap: The Evolving State of the Science in EGFR+ NSCLC—A Closer Look at the Paradigm-Shifting Synergy of Safety, Efficacy, and Equitable Access

This Rapid Recap will provide a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting, and offer expert insights into the shifting management landscape for metastatic EGFR+ NSCLC.

 

1.00
07/06/2022

Natasha B. Leighl

Thoracic Medical Oncology Group, Princess Margaret Cancer Centre
Professor, Department of Medicine
Adjunct Professor, Institute of Health Policy Management and Evaluation
University of Toronto, Toronto, ON, Canada

Natasha B. Leighl

Thoracic Medical Oncology Group, Princess Margaret Cancer Centre,
Professor, Department of Medicine,
Adjunct Professor, Institute of Health Policy Management and Evaluation,
University of Toronto, Toronto, ON, Canada

Helena Yu

Lung Cancer Medical Oncologist,
Memorial Sloan Kettering Cancer Center,
New York, NY

Helena Yu

Lung Cancer Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Jill Feldman

Lung Cancer Patient and Advocate
Chair, IASLC Patient Advocacy Committee
Co-Founder EGFR Resisters
Deerfield Park, IL

Jill Feldman

Lung Cancer Patient and Advocate
Chair, IASLC Patient Advocacy Committee
Co-Founder EGFR Resisters
Deerfield Park, IL

Appraising Current Safety and Efficacy Data for PARP Inhibitors in Ovarian Cancer: Best Practices in Treatment and Adverse Event Management

Expert faculty for this 30-minute webinar will include a gynecologic oncologist and a nurse. This webinar will provide an overview of the latest data in PARP inhibitor therapy for the treatment of ovarian cancer in patients with different biomarker profiles and at different stages of the disease. Recent clinical data and rationale for PARP inhibitor use in the first-line maintenance setting will be discussed. Faculty will share unique toxicity profiles among the different PARP inhibitors and best practices in monitoring, preventing, and treating adverse events that may arise with therapy.

0.5
07/12/2022

Jennifer Filipi

Center for Gynecologic Oncology,
Massachusetts General Hospital,
Boston, MA

Jennifer Filipi

Center for Gynecologic Oncology
Massachusetts General Hospital
Boston, MA

Beth Y. Karlan, MD

Professor and Vice Chair of Women's Health Research
Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA
Director, Cancer Population Genetics
UCLA-Jonsson Comprehensive Cancer Center, Los Angeles, CA

Beth Y. Karlan, MD

Professor and Vice Chair of Women’s Health Research
Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA
Director, Cancer Population Genetics
UCLA-Jonsson Comprehensive Cancer Center, Los Angeles, CA

On-Demand
Webinar
0.5
07/12/2022

Digging Deep into the Genome: What Genetic Testing Can (and Can’t) Tell Us about Ovarian Cancer

Expert faculty for this 30-minute webinar will include a pathologist and a gynecologic oncologist. Faculty will summarize the latest guidelines on genes that should be tested in ovarian cancer and the appropriate identification of patients who should receive testing.

0.5
07/12/2022

Beth Y. Karlan, MD

Professor and Vice Chair of Women's Health Research
Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA
Director, Cancer Population Genetics
UCLA-Jonsson Comprehensive Cancer Center, Los Angeles, CA

Beth Y. Karlan, MD

Professor and Vice Chair of Women’s Health Research
Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA
Director, Cancer Population Genetics
UCLA-Jonsson Comprehensive Cancer Center, Los Angeles, CA

Joseph W. Carlson, MD, PhD

Professor of Clinical Pathology
Department of Pathology, USC Keck School of Medicine
University of Southern California, Los Angeles, CA

Joseph W. Carlson, MD, PhD

Professor of Clinical Pathology
Department of Pathology, USC Keck School of Medicine
University of Southern California, Los Angeles, CA

Recognizing and Addressing the Elephant in the Room: Multidisciplinary Strategies to Mitigate Disparities in Ovarian Cancer Patients

Expert faculty for this 30-minute webinar will include perspectives from a patient, a medical oncologist, and an oncology nurse.

0.5
07/12/2022

Beth Y. Karlan, MD

Professor and Vice Chair of Women's Health Research
Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA
Director, Cancer Population Genetics
UCLA-Jonsson Comprehensive Cancer Center, Los Angeles, CA

Beth Y. Karlan, MD

Professor and Vice Chair of Women’s Health Research
Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA
Director, Cancer Population Genetics
UCLA-Jonsson Comprehensive Cancer Center, Los Angeles, CA

Paula Anastasia MN, RN, AOCN

GYN OncologyAdvanced Practice Nurse
UCLA Health, Los Angeles, CA

Paula Anastasia MN, RN, AOCN

GYN OncologyAdvanced Practice Nurse
UCLA Health, Los Angeles, CA

Carol Tokeshi

Carol Tokeshi

On-Demand
Webinar
1.0
07/19/2022

Evolving Treatment Paradigms for Bladder Cancer: Expert Perspectives on the Latest Data

Bladder cancer thought leaders Drs. Sam Chang and Shilpa Gupta review the rapidly evolving bladder cancer treatment landscape across the full continuum of care, from emerging data in NMIBC, to novel neoadjuvant and adjuvant regimens in MIBC, to robust paradigmatic changes in locally advanced and mUC, both in the front-line setting and in subsequent lines of therapy.

1.0
07/19/2022

Sam S. Chang MD, MBA



Sam S. Chang MD, MBA

Professor, Department of Urology
Patricia and Rodes Hart Professor of Urologic Surgery
Chief Surgical Officer
Division of Urologic Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN

Shilpa Gupta, MD

Director of the Genitourinary Medical Oncology
Cleveland Clinic
Co-Leader of the Genitourinary Oncology Program
Taussig Cancer Institute, Cleveland, OH

Shilpa Gupta, MD

Director of the Genitourinary Medical Oncology
Cleveland Clinic
Co-Leader of the Genitourinary Oncology Program
Taussig Cancer Institute, Cleveland, OH

On Demand: Harnessing the Power of Immunotherapy in HCC and BTC: An Expert Exploration of the Past, Present, and Future of Checkpoint Inhibition

This session will review the totality of emerging evidence for immune checkpoint inhibitors (ICIs) in the hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) management calculus.

1.00
09/23/2022

James J. Harding, MD

Medical Oncologist
Gastrointestinal Oncology Service, Department of Medicine
Memorial Sloan Kettering Cancer Center, New York, NY

James J. Harding, MD

Medical Oncologist
Gastrointestinal Oncology Service, Department of Medicine
Memorial Sloan Kettering Cancer Center, New York, NY

R. Katie Kelley, MD

Professor of Clinical Medicine
Department of Medicine (Hematology/Oncology)
University of California, San Francisco
San Francisco, CA

R. Katie Kelley, MD

Professor of Clinical Medicine
Department of Medicine (Hematology/Oncology)
University of California, San Francisco
San Francisco, CA

Riad Salem, MD, MBA

Professor of Radiology, Medicine and Surgery
Chief, Section of Vascular and Interventional Radiology
Vice-Chair, Image-Guided Therapy, Department of Radiology
Northwestern University, Chicago, IL

Riad Salem, MD, MBA

Professor of Radiology, Medicine and Surgery
Chief, Section of Vascular and Interventional Radiology
Vice-Chair, Image-Guided Therapy, Department of Radiology
Northwestern University, Chicago, IL